Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Documentation of Efficacy for Intralymphatic Allergen Immunotherapy in a Phase III Randomized, Parallel Group, Double Blind Placebo-controlled Multisite Field Trial

NCT05297760 is registered in ClinicalTrials.gov with University of Zurich as lead sponsor.

NCT NCT05297760
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05297760 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Documentation of Efficacy for Intralymphatic Allergen Immunotherapy in a Phase III Randomized, Parallel Group, Double Blind Placebo-controlled Multisite Field Trial
Lead sponsor
University of Zurich
Phase
Phase 1/2
Overall status
Completed
Start date
February 10, 2022
Completion date
February 28, 2025
Enrollment
60 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

allergic asthma, allergic rhinitis, allergic rhinitis due to grass pollen, rhinitis, allergic, seasonal, rhinitis; allergic, with asthma